ZSTK474

Target: This ligand targets class I phosphoinositide 3-kinases PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for class I phosphoinositide 3-kinases PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings class I phosphoinositide 3-kinases PI3Kα into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Based Kinase Degradation: ZSTK474 can be leveraged as a kinase-binding ligand to construct PROTACs that recruit an E3 ligase and drive selective degradation of its intended kinase target. This enables functional interrogation beyond inhibition, allowing researchers to assess pathway dependency, compensatory signaling, and degradation kinetics in cellular and biochemical systems.

• E3 Ligase Recruitment Optimization: ZSTK474-derived PROTACs can be designed with varied linker lengths and E3 ligase recruiters to tune ternary complex formation and ubiquitination efficiency. Systematic optimization helps identify conditions that maximize target ubiquitination and proteasome-mediated clearance, improving signal-to-noise for downstream phosphoproteomic and phenotypic readouts.

• Pathway Mechanism Dissection: Using ZSTK474 in PROTAC formats supports mechanism studies that distinguish catalytic inhibition from complete protein loss. Researchers can compare degradation-driven phenotypes with inhibitor controls to determine whether observed effects stem from target depletion, altered substrate availability, or network rewiring.

• Proteasome-Dependent Turnover Studies: ZSTK474-based PROTACs are suited for experiments probing degradation mechanisms, including proteasome dependence and ubiquitin linkage patterns. By combining PROTAC treatment with proteasome or ubiquitination pathway perturbations, investigators can quantify turnover rates and map degradation sensitivity across cell models.

ZSTK474 is a PI3K pathway ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of ZSTK474 is characterized by primary or secondary amine/basic nitrogen centers; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.